Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Gilead study: remdesivir has marginal benefit for moderate COVID patients

Published 08/21/2020, 01:14 PM
Updated 08/21/2020, 01:15 PM
© Reuters. The spread of the coronavirus disease (COVID-19) in Hamburg

By Deena Beasley

(Reuters) - Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc (NASDAQ:GILD)'s remdesivir, but a 10-day course did not show a benefit and the drug did not significantly shorten hospital stays, according to new data.

The 600-patient analysis, published on Friday by the Journal of the American Medical Association, found that moderately-ill patients treated with the antiviral drug for up to 5 days had significantly higher odds of improvement compared to patients given standard treatment. But researchers said the clinical importance of the benefit was uncertain.

Remdesivir is currently used under an emergency use authorization from the U.S. Food and Drug Administration for treating patients hospitalized with severe COVID-19, the disease caused by the new coronavirus. Gilead earlier this month filed an application seeking full FDA approval of the drug.

The drug, which was shown in a trial of severe COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.

Latest comments

Inhaled version made by TFFP was a major improvement. Watch for this, everyone. Thin film freezing can be used to make inhalers for all kinda if drugs. Including vaccines. Aimed right into the lungs. Very excited. Holding their stock LONG and strong.
Remember when a trial on Remdesivir was halted because the researchers felt it was unethical to continue the trial and not give Remdesivir to the control group? Well, now Ivermectin has proven effective as part of a cocktail. almost 100% effective even in hospitalised cases (vs mildly effective for mild cases) and at 1/100 the cost of Remdesivir. Turns out that cheap, re-tasked meds originally made decades ago don't have a well paid marketing department. Where there isn't money to be made, there are few cheerleaders.
There was a guy here in Prague, a cab driver actually, who was an inch from not making it. He was intubated and put into induced coma. The last resort was Remdesivir. It was obtained from the US and applied to the patient. He made it thanks to the drug. There was a press conference where he cried and thanked the doctors in the hospital. I was thinking why isn't this drug prescribed to every patient that is getting worse...?
Because it has marginal benefit - the clue is in the title of the article. That and $2500 for a 5 dose course
The drug rlf-100 is the only thing I have seen that seems to get results. it helps the very sick, but once they release the inhaler version, it could help much more.
rlftf rlf-100 is where its at.
I knew it. They will be doing this to vaccines aswell. Curing people is not a profitable business. Menaging symptoms however...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.